Epigenetic aging biomarkers in dietary geroscience: feasibility, participant perceptions, and trial design considerations

Lindsay M Reynolds, Timothy D Howard, Carl D Langefeld, Mara Z Vitolins · 2026

Read Epigenetic aging biomarkers in dietary geroscience: feasibility, participant perceptions, and trial design considerations by Lindsay M Reynolds, Timothy D Howard, Carl D Langefeld, Mara Z Vitolins (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13601483.txt.

Description

Lindsay M Reynolds and three colleagues report a 2026 pilot study on whether aging clocks fit into diet trials. Geroscience aims to slow aging biology itself. DNA-based measures can estimate biological age and pace of aging, yet few diet studies have tested whether such measures are practical to collect. The team ran a four-week trial in 34 adults aged 48 to 81 who had metabolic syndrome.

Participants ate an ounce of tree nuts and two tablespoons of olive oil daily. Adherence topped 95 percent, and most would join a longer one. At the start, every participant aged faster than average on the DunedinPACE measure, supporting metabolic syndrome as a target group. Participants wanted to learn their biological age, and said proof of slower aging would motivate lasting change. Four weeks brought no measurable shift in the aging markers. The approach is feasible and engaging, the authors conclude, with design lessons for longer trials.

Catalog record

CREATORLindsay M Reynolds, Timothy D Howard, Carl D Langefeld, Mara Z Vitolins
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13601483

Browse the full library · About the Tower of Babel